NCT06401824 - Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2025

Primary Completion Date

November 1, 2026

Study Completion Date

April 1, 2027

Conditions

NSCLC Stage IVBrain Metastases, Adult

Interventions

DRUG

Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab

Sacituzumab govitecan 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression.

Trial Locations (3)

Unknown

RECRUITING

NKI-AvL, Amsterdam

RECRUITING

University Medical Center Groningen, Groningen

RECRUITING

Maastricht University Medical Center, Maastricht